ByTrending Posts
Top 10 Pharma Brands of 2025 — Sales…
The pharmaceutical market in 2025 was defined by high-value specialty brands delivering breakthrough outcomes in oncology, metabolic disease,…
Big Pharma Accelerates Shift to Off-the-Shelf Cell Therapy…
The global biopharmaceutical industry is entering a new phase in cell therapy innovation, marked by significant investments in…
Drugmakers Use AI to Speed Trials and Regulatory…
Pharmaceutical companies are increasingly using artificial intelligence to streamline clinical trials and regulatory filings. While AI has not…
AI Is Reshaping Pharma’s Economics—But Discovery Isn’t the…
Executive Summary Artificial intelligence has moved from experimental promise to operational backbone across global biopharma. Industry leaders including…
Can Takeda’s $1.7 Billion Iambic Deal Redefine AI-Driven…
Executive Summary In a landmark AI-biopharma transaction, Takeda Pharmaceutical Co Ltd has entered a multi-year collaboration valued at…
Pfizer Repositions for Sustainable Growth in 2025 as…
Pfizer Inc. reported full-year 2025 revenues of $62.6 billion, marking a pivotal year in the company’s post-pandemic transformation.…
Eli Lilly Delivers Transformational Growth in 2025, Anchored…
Indianapolis, IN – February 2026 – Eli Lilly and Company reported exceptional full-year financial and operational performance in…
Merck Reinforces Oncology Leadership and Therapeutic Area Depth…
Rahway, NJ – February 2026 – Merck & Co., Inc. reported strong full-year 2025 financial and operational performance,…
AbbVie Accelerates Portfolio-Led Growth in 2025 and Strengthens…
North Chicago, IL – February 2026 – AbbVie Inc. reported a strong full-year financial performance in 2025, underscoring…
Trending Posts
Latest Stories
How Does Pfizer Transform Oncology Supremacy Into Sustainable Growth Beyond COVID Glory?
Pfizer engineers a “diversified oncology fortress” strategy featuring 108 pipeline candidates (one-third new molecular entities) across oncology,…
How Does Merck Architect a $70 Billion Post-Keytruda Fortress Through 2030?
Merck executes a “One Pipeline” diversification masterplan, tripling late-stage assets since 2021 to deliver 20+ potential…
How Does Sanofi Transform Immunology Dominance Into €20+ Billion Revenue Through 2030?
Sanofi masterminds a “multi-indication immunology powerhouse” strategy, surgically channeling R&D toward 12 blockbuster candidates (3 “pipeline-in-a-product” assets…
How Does Novo Nordisk Transform Metabolic Leadership Into Multi-Billion Dollar Dominance Through 2030?
Novo Nordisk executes a “multi-mechanism obesity fortress” strategy under new CEO Mike Doustdar, reallocating R&D firepower from…
Gallery
